Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous Midazolam during Bronchoscopy: A commentary

Pharmacotherapy

Volumn 33, Issue 5, 2013, Pages

  Brackett, Carolyn C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; MIDAZOLAM; PROTEINASE INHIBITOR;

BRONCHOSCOPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE; LIVER; NOTE; SEDATION; SIDE EFFECT;

BRONCHOSCOPY; DEEP SEDATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM;

EID: 84879360587     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1200_1     Document Type: Note

References (3)

1. Hsu AJ, Carson KA, Yung R, Pham PA. Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy. Pharmacotherapy 2012;32(6):538-545.
2. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A4 activity and elvitegravir oral exposure. Clin Pharmacol Ther 2008;85:64-70.
3. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic P450 3A4 activity with midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-471.